MedTrace Logo

Bone Marrow vs Liver as Site for Islet Transplantation

NCT01722682 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-11-04

No results posted yet for this study

Summary

The goal of this study is to evaluate safety and efficacy of bone marrow (BM) as site for pancreatic islet transplantationin humans. Our hypothesis is that BM represents a better site than liver (currently the location of choice for this procedure) thanks to its potential capacity to favor islet engraftment. To address our hypothesis we propose herein a randomized phase II trial to compare BM and liver as sites for islet transplantation in T1D patients.

Conditions

Interventions

BIOLOGICAL

Human pancreatic islet transplantation

Sponsors & Collaborators

  • Ministry of Health, Italy

    collaborator OTHER_GOV

  • Ospedale San Raffaele

    lead OTHER

Principal Investigators

  • Lorenzo Piemonti, MD · Ospedale San Raffaele

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2017-09-30
Completion
2017-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01722682 on ClinicalTrials.gov